Introduction
============

The incidence of oesophageal adenocarcinoma (AC), for which the 5-year survival rate is 13.6%\[[@b1]\], has increased in the United States and Western countries for poorly understood reasons over the past three decades. Early detection is critical to treatment success, and is based on endoscopic surveillance of dysplasia in the pre-malignant condition, Barrett\'s oesophagus (BE), characterized by metaplastic columnar oesophageal epithelial cells. BE increases the risk of AC by some 40- to 125-fold \[[@b2]\], and provides an opportunity for early intervention. Several studies have identified genes or gene expression patterns that are characteristic of BE or AC \[[@b3]\], and several markers identify patient subsets at high risk for progression, including aneuploidy, p53 loss of heterozygosity and p16INK4a (CDKN2A) abnormalities \[[@b6]\]. However, not all patients with these abnormalities progress, and there is therefore a need to identify additional indicators of risk.

The p14ARF tumour suppressor (hereafter referred to as 'ARF', for Alternate Reading Frame) is estimated to be silenced in some 30% of cancers overall \[[@b9]\], making it one of the most frequently altered genes in human cancer, and a possible indicator of progression. ARF plays a well-established role in activating the p53 tumour suppressor pathway in response to oncogenic hyperproliferative signals \[[@b10]\], and in addition engages in less well-understood p53-independent functions \[[@b11]\]. In AC, the specific role of ARF gene silencing has not been addressed, and CpG methylation of ARF, a common mechanism of tumour suppressor gene silencing in cancer \[[@b15]\], has been observed in tumour specimens with variable frequencies in different studies, up to about 30%\[[@b16]\]. The possibility that disease progression could involve quantitative changes in ARF expression levels, and the possible involvement of other silencing mechanisms such as histone modifications has not been examined. We have therefore used clinical specimens of normal oesophageal epithelium (NE), BE, and AC, and early passage cell lines derived from these tissue types, to examine possible changes in ARF expression during disease progression, as well as molecular mechanisms that may be involved.

Materials and methods
=====================

Cell culture
------------

Barrett\'s and oesophageal cell lines that closely model the tissue of origin \[[@b19]\] and were at early passage (less than passage 20) were maintained at 37°C in 10% CO2 in DMEM supplemented with nonessential amino acids, pyruvate, L-glutamine, gentamicin, and 10% FBS, except for Gohtert Gihtert, Chtert and Het1A, for which 20% FBS was added. [Table 1](#tbl1){ref-type="table"} lists the cell line characteristics and source.

###### 

Cell lines

  **Cell line**                                     **Description**                                                                                                                 **Source**                                          **p53 status[\*](#tf1-3){ref-type="table-fn"}[\*](#tf1-3){ref-type="table-fn"}**
  ------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------- ----------------------------------------------------------------------------------
  HET1A                                             Normal human epithelial cells immortalized with SV40 T-antigen                                                                  American Type Culture Collection (ATCC)             Wild-type
  BJ-1                                              Normal human fibroblast cells immortalized with human telomerase                                                                American Type Culture Collection (ATCC)             Wild-type
  OE33                                              Oesophageal adenocarcinoma                                                                                                      European Collections of Cell Cultures (ECACC)       Codon 135, TGC(cys)→TAC(tyr)
  TE7                                               Oesophageal adenocarcinoma[\*](#tf1-3){ref-type="table-fn"}[\*](#tf1-3){ref-type="table-fn"}[\*](#tf1-3){ref-type="table-fn"}   Dr. T. Nishihira, Kurokawa County Hospital, Japan   Null
  SEG1                                              Oesophageal adenocarcinoma                                                                                                      Dr. D.G. Beer, University of Michigan, USA          Wild-type
  FLO                                               Oesophageal adenocarcinoma                                                                                                      Dr. D.G. Beer, University of Michigan, USA          Codon 277, TGT(cys)→TTT(phe)
  OC1                                               Oesophageal squamous cell carcinoma                                                                                             Dr. O\'Sullivan, Cork Cancer Center, Ireland        Wild-type
  OC3                                               Oesophageal adenocarcinoma                                                                                                      Dr. O\'Sullivan, Cork Cancer Center, Ireland        Codon 244, GGC(gly)→GAC(asp)
  Gihtert[\*](#tf1-3){ref-type="table-fn"} (CP-C)   Barrett\'s oesophagus cells immortalized with human telomerase                                                                  Dr. J. Anderson, University of Washington, USA      Codon 248, CGG(arg)→TGG(trp)
  Gohtert[\*](#tf1-3){ref-type="table-fn"} (CP-D)   Barrett\'s oesophagus cells immortalized with human telomerase                                                                  Dr. J. Anderson, University of Washington, USA      Codon 302, GGG(gly)→GG- (frameshift)
  Chtert[\*](#tf1-3){ref-type="table-fn"} (CP-B)    Barrett\'s oesophagus cells immortalized with human telomerase                                                                  Dr. J. Anderson, University of Washington, USA      Codon 175, CGC(arg)→CAC(his)

\(1\) Barrett, M. T., *et al.*Cancer Res, 63:4211--4217, 2003; (2) Palanca-Wessels, M. C., *et al*. Carcinogenesis, 24:1183--1190, 2003.

[\*](#tf1-3){ref-type="table-fn"}Determined by RT-PCR sequencing of exons 5--9.

[\*](#tf1-3){ref-type="table-fn"}[\*](#tf1-3){ref-type="table-fn"}Presently used lines likely to be of oesophageal squamous cell origin (Boonstra *et al.*, Cancer Res. *67*:7996--8001, 2007).

Tissue specimens
----------------

Twenty biopsies of normal squamous oesophagus (in patients without Barrett\'s oesophagus) and 20 biopsies of Barrett\'s oesophagus were collected from Addenbrooke\'s Hospital in Cambridge (by R.C.F) and University College Hospital in London, in collaboration with Dr. Laurence Lovat. Histological diagnosis was verified by pathological examination of paired biopsies taken for clinical purposes from the same endoscopic site. The 76 adenocarcinoma samples were pre-treatment biopsies obtained from Professor Hugh Barr at Gloucester NHS Trust and Professor Derek Alderson at Bristol Royal Infirmary. Patients were subsequently treated with esophagectomy. For all adenocarcinoma samples, histology was confirmed on a frozen section taken from the research specimen by two independent pathologists (Professor Neil Shepherd and Professor Brian Warren for Gloucester samples and the reporting clinical pathologist in addition to Dr. Vicki Save for Bristol samples). All the samples were taken from the lower part of oesophagus, 2 cm above the oesophago-gastric junction, and were processed for research if epithelial cellularity was \>80%. Ethics Committee approvals from each participating institution were obtained for these studies, and written informed consent was obtained from the participating patients.

RT-PCR and PCR
--------------

Total RNA or DNA prepared from cells or frozen tissue using Triozol Reagent (Invitrogen, Carlsbad, CA, USA) according to the protocol supplied by the manufacturer was subjected to RT-PCR or PCR, respectively using primers chosen to amplify a gene fragment of about 300--600 bases. Primers were synthesized by Sigma (Genosys, Woodlands, TX, USA) and are listed in [Table 2](#tbl2){ref-type="table"}. The conditions used were as follows: 95°C (2 min.), followed by 40 cycles of 95°C (30 sec), 58°C (30 sec.) and 72°C (30 sec).

###### 

Primer sequences

  **Primer name**         **Application**         **Sequence**
  ----------------------- ----------------------- --------------------------------------------------------------------------------------------
  ARF-forward             RT-PCR                  5′-ATGGGCAGGGGGCGGTGCGT-3′
  ARF reverse             RT-PCR                  5′-TCAGCCAGGTCCACGGGCAGA-3′
  GAPDH-forward           RT-PCR                  5′-GAAGGTGAAGGTCGGAGTC-3′
  GAPDH-reverse           RT-PCR                  5′-GAAGATGGTGATGGGATTTC-3′
  ARF exon lβ-forward     PCR                     5′-TGGGTCCCAGTCTGCAGTTA-3′
  ARF exon 1ß-reverse     PCR                     5′-GGCTCCTCAGTAGCATCAGC-3′
  ARF exon 2-forward      PCR                     5′-CACTCTCACCCGACCCGT-3′
  ARF exon 2-reverse      PCR                     5′-ACCTTCCGCGGCATCTAT-3′
  M-forward               MSP                     5′-GTCGAGTTCGGTTTTGGAGG-3′ (-30 from translation start)[\*](#tf2-1){ref-type="table-fn"}
  M-reverse               MSP                     5′-AAAACCACAACGACGAACG-3′ (133 from translation start)[\*](#tf2-1){ref-type="table-fn"}
  U-forward               MSP                     5′-TGAGTTTGGTTTTGGAGGTGG-3′ (-28 from translation start)[\*](#tf2-1){ref-type="table-fn"}
  U-reverse               MSP                     5′-AACCACAACAACAAACACCCCT-3′ (131 from translation start)[\*](#tf2-1){ref-type="table-fn"}
  ARF ChIP Forward        ChIP                    5′-ATGGGCAGGGGGCGGTG-3′ (-123 from translation start)[\*](#tf2-1){ref-type="table-fn"}
  ARF ChIP Reverse        ChIP                    5′-CTGGTCTTCTAGGAAGCGGCT-3′ (192 from translation start)[\*](#tf2-1){ref-type="table-fn"}
  ARF universal forward   Bisulphite sequencing   5′-TTGTTTATTTTTGGTGTTAAAGGG-3′ (-67 from start)[\*](#tf2-1){ref-type="table-fn"}
  ARF universal reverse   Bisulphite sequencing   5′-CCTTTCCTACCTAATCTTCTAAAAAAC-3′ (+203 from start)[\*](#tf2-1){ref-type="table-fn"}

The 5′ position of the primers relative to the start of translation (base pair 161 of GenBank sequence number I/IM_058195) is indicated in parentheses.

Methylation-specific PCR (MSP)
------------------------------

CpG island methylation analysis was determined using bisulphite-treated genomic DNA following the instructions of EZ DNA methylation kit (Zymo research, Orange, CA, USA). Primers specific for the methylated strand (M) and unmethylated strand (U) of the ARF promoter/exon1 **(J** were used, and were designed to include 5 CpG sites and 9 CpG sites in the M and U primers, respectively in order to maximize specificity. Positive and negative controls were carried out using *in vitro* CpG methylated human sperm DNA with *SssI* (CpG) methylase (New England Biolabs, Inc., Beverly MA, USA) or unmethylated sperm DNA, respectively. The primer sequences are listed in [Table 2](#tbl2){ref-type="table"}, and conditions were as described for RT-PCR. Methylated sites within the PCR amplified regions were determined by sequencing the purified MSP products.

Q-PCR and Q-MSP
---------------

Real-time quantitative PCR (Q-PCR) was optimized by melt-curve analysis, and efficiency was calculated by serial dilutions. ARF-expressing BJ-1 cells and ARF-null TE7 cells were used as positive and negative controls, respectively. cDNA prepared from tissue or cellular RNA was diluted 1:10 and 5 μl was amplified in a 20 μl volume (in triplicate) containing 10 μl of Sigma SYBR Green PCR Master Mix (Sigma-Aldrich) and 0.2 μmol/l final concentration of each primer, using a Rotor-Gene 3000 Real-time PCR cycler (Westburg Genomics, the Netherlands), using conditions described for RT-PCR. Gene expression was measured relative to GAPDH (glyceraldehyde phosphate dehydrogenase) and was expressed as Relative Transcript Abundance = 1000/2^(C\ RF\ −\ CTGAPDH^), where C~T~= threshold cycle. The primers for ARF and GAPDH were the same as those described for RT-PCR and are listed in [Table 2](#tbl2){ref-type="table"}, and conditions were as described for RT-PCR.

Quantitative MSP (Q-MSP) analysis of bisulphite-treated DNA was performed similarly (in triplicate). The levels of unmethylated and methylated species were determined by a standard curve constructed by serial dilutions of unmethylated or *SssI*-methylated human sperm DNA, respectively. Dilution experiments showed linearity of amplification down to a dilution of 1:10^4^ for methylated DNA as well as for unmethylated DNA. The primers used were the same as for MSP and are listed in [Table 2](#tbl2){ref-type="table"}, and PCR conditions were as described for RT-PCR.

Bisulphite sequencing
---------------------

Two micrograms genomic DNA was bisulphite-treated and used for PCR amplification of a 270 base pair region with universal primers listed in [Table 2](#tbl2){ref-type="table"}, and conditions described for RT-PCR. The PCR product was gelpurified and sequenced using the same primers.

Chromatin immunoprecipitation (ChIP)
------------------------------------

ChIP assays were performed following the chromatin immunoprecipitation protocol on the Upstate website ([<http://www.upstate.com>]{.ul}). Two micrograms of anti-trimethyl-histone H3 (Lys-9) antibody (07--442, Upstate, USA) and anti-dimethyl-histone H3 (lys-9) antibody (ab7312, shared epitope with H3-lys-27, Abcam, UK) was used for each ChIP reaction. ARF sequences in the immunoprecipitates and starting material (input) were detected by PCR using ARF ChIP primers listed in [Table 2](#tbl2){ref-type="table"}, and conditions described for RT-PCR.

Statistical analyses
--------------------

The significance of differences in ARF expression data in tissue specimens was determined by a Kruskal-Wallis rank sum test. Kaplan--Meier survival curves were evaluated by a Log Rank (Mantel-Cox) test. For multivariate analysis, a Cox regression model using a backward stepwise method was utilized. Fisher\'s exact test was used to determine if the ARF expression status was associated with the N-Stage of the tumour.

Results
=======

ARF expression and gene status in clinical specimens
----------------------------------------------------

ARF expression was examined by quantitative PCR (Q-PCR) in prospectively collected clinical specimens of oesophageal tissue from individuals with a normal squamous oesophagus (20 specimens) and patients with non-dysplastic BE (20 specimens) or AC (76 specimens). We found highly significant decreases in ARF expression (P \< 0.001) with disease progression from normal oesophageal epithelium (NE), to non-dysplastic BE to AC ([Fig. 1A](#fig01){ref-type="fig"}). Furthermore, 57 of 76 (75%) AC specimens had undetectable levels of ARF expression, while only 4 of 20 (20%) BE specimens and none of the NE specimens displayed undetectable levels of ARF expression. [Table 3](#tbl3){ref-type="table"} summarizes the ARF expression analysis for the 47 AC specimens for which follow-up data were available.

![Relative ARF expression in NE, BE and AC tissue specimens and correlation with patient survival. (**A**) Quantitative RT-PCR analysis of tissue specimens from normal oesophageal epithelium (NE, *n*= 20), Barrett\'s oesophagus (BE, *n*= 20) and oesophageal adenocarcinoma (AC, *n*= 76) using primers specific for ARF exon 1ß. ARF expression (average of triplicates) relative to glyceraldehyde phosphate dehydrogenase (GAPDH) is shown. Median values for each dataset are indicated by horizontal lines. The significance of the differences between datasets was evaluated by a Kruskal-Wallis rank sum test and P values are indicated above each pair of sets. (**B**) Kaplan-Meier survival curves of adenocarcinoma patients whose tumour either expressed ARF (*n*= 13) or lacked expression of ARF (*n*= 34). The difference between the curves was highly significant (x^2^= 21.69, d.f. = 1, *P*\< 0.001, based on a Log-Rank Mantel-Cox test).](jcmm0013-0398-f1){#fig01}

###### 

Correlation of ARF expression and survival in AC patients (*n*= 47)

  **Differentiation**   **Sex**   **Age**   **T stage[\*](#tf3-1){ref-type="table-fn"}**   **N stage[\*](#tf3-1){ref-type="table-fn"}**   **DPR[\*](#tf3-1){ref-type="table-fn"}**   **DPD[\*](#tf3-1){ref-type="table-fn"}**   **Dead or alive at last follow-up**   **ACT[\*](#tf3-1){ref-type="table-fn"}**   **Relative ARF expression[\*](#tf3-1){ref-type="table-fn"}**
  --------------------- --------- --------- ---------------------------------------------- ---------------------------------------------- ------------------------------------------ ------------------------------------------ ------------------------------------- ------------------------------------------ --------------------------------------------------------------
  Moderate              M         80        2                                              0                                              NR                                         4137                                       Alive                                 4.09                                       58.72
  Poorly                M         74        2                                              1                                              NR                                         3188                                       Alive                                 4.76                                       36.91
  Moderate              M         48        2                                              1                                              2918                                       2918                                       Dead                                  5.4                                        23.68
  Moderate              M         44        3                                              1                                              2371                                       2602                                       Dead                                                                             N
  Moderate              M         64        3                                              1                                              NR                                         2597                                       Alive                                 8.69                                       2.42
  Moderate              M         56        1                                              0                                              NR                                         2313                                       Alive                                 4.36                                       48.70
  Well                  M         63        1                                              0                                              NR                                         2249                                       Alive                                 7.33                                       6.22
  Well                  M         78        1                                              0                                              NR                                         2060                                       Alive                                 6.15                                       14.08
  Poorly                F         63        3                                              1                                              NR                                         2045                                       Alive                                 7.81                                       4.46
  Moderate              M         66        2                                              1                                              NR                                         1984                                       Alive                                 8.57                                       2.63
  Well                  M         66        2                                              1                                              1576                                       1723                                       Dead                                                                             N
  Well                  M         70        2                                              1                                              1339                                       1583                                       Dead                                                                             N
  Poorly                M         71        3                                              1                                              1550                                       1575                                       Dead                                                                             N
  Poorly                M         76        3                                              1                                              1550                                       1575                                       Dead                                                                             N
  Moderate              F         65        2                                              0                                              289                                        1533                                       Dead                                  8.82                                       2.21
  Moderate              M         68        3                                              1                                              1450                                       1450                                       Dead                                                                             N
  Moderate              F         51        3                                              0                                              1219                                       1339                                       Dead                                                                             N
  Moderate              M         74        3                                              1                                              815                                        1327                                       Dead                                                                             N
  Poorly                M         69        3                                              1                                              555                                        1172                                       Dead                                                                             N
  Moderate              M         75        3                                              1                                              845                                        859                                        Dead                                                                             N
  Poorly                F         73        3                                              1                                              566                                        816                                        Dead                                                                             N
  Moderate              M         69        2                                              0                                              721                                        721                                        Dead                                  9.27                                       1.62
  Poorly                M         56        2                                              1                                              524                                        687                                        Dead                                                                             N
  Moderate              F         69        2                                              0                                              489                                        545                                        Dead                                                                             N
  Poorly                M         74        2                                              1                                              449                                        510                                        Dead                                                                             N
  Well                  M         68        3                                              1                                              428                                        480                                        Dead                                                                             N
  Poorly                M         51        3                                              1                                              357                                        477                                        Dead                                                                             N
  Poorly                M         69        3                                              1                                              370                                        473                                        Dead                                                                             N
  Poorly                M         47        3                                              1                                              277                                        446                                        Dead                                                                             N
  Moderate              M         66        2                                              1                                              298                                        397                                        Dead                                                                             N
  Poorly                M         NA        3                                              1                                              264                                        389                                        Dead                                                                             N
  Poorly                M         53        3                                              1                                              317                                        347                                        Dead                                                                             N
  Moderate              F         50        3                                              1                                              314                                        343                                        Dead                                                                             N
  Poorly                F         74        3                                              1                                              153                                        238                                        Dead                                                                             N
  Poorly                M         76        3                                              1                                              94                                         227                                        Dead                                  6.22                                       13.42
  Well                  M         48        3                                              1                                              118                                        207                                        Dead                                                                             N
  Poorly                M         72        3                                              1                                              192                                        192                                        Dead                                                                             N
  Moderate              M         46        3                                              1                                              129                                        176                                        Dead                                                                             N
  Poorly                M         54        3                                              1                                              93                                         174                                        Dead                                                                             N
  Poorly                F         69        2                                              1                                              101                                        169                                        Dead                                                                             N
  Poorly                M         82        3                                              1                                              103                                        166                                        Dead                                                                             N
  Poorly                M         50        3                                              1                                              118                                        166                                        Dead                                                                             N
  Poorly                M         67        3                                              1                                              149                                        164                                        Dead                                                                             N
  Moderate              M         89        2                                              1                                              92                                         132                                        Alive                                 9.77                                       1.15
  Well                  M         NA        1                                              0                                              129                                        129                                        Dead                                                                             N
  Moderate              M         80        3                                              1                                              0                                          77                                         Dead                                                                             N
  Poorly                M         50        2                                              1                                              41                                         41                                         Dead                                                                             N

T stage = tumour stage; N stage = nodal status; DPR = days prior to relapse; NR = no relapse; DPD = days prior to death or last known alive; Relative ARF expression = 1000/2^ΔCT^; ΔCT = CT~[arf]{.smallcaps}~-- CT~[gapdh]{.smallcaps}~; (CT~[gapdh]{.smallcaps}~ varied by \<10% amongst samples); N = not measurable.

Correlation of ARF expression with clinical outcome
---------------------------------------------------

Among the 76 AC patients whose tumours were analysed for ARF expression in [Figure 1A](#fig01){ref-type="fig"}, clinical data relating to disease stage and survival were available for 47 patients ([Table 3](#tbl3){ref-type="table"}). Only T-stage (Log rank Mantel-Cox test, χ^2^= 7.65, d.f. = 2, P = 0.022), and ARF expression (Log rank Mantel-Cox test, χ^2^= 21.69, d.f. = 1, P \< 0.0001, see [Fig. 1B](#fig01){ref-type="fig"}) were prognostically significant on univariate analysis, though the N-Stage approached statistical significance (Log rank Mantel-Cox test, χ^2^= 3.72, d.f. = 1, P = 0.052). Retaining ARF expression significantly improved survival, and even low levels of ARF seemed to provide a barrier to tumourigenic progression. When entering differentiation, T-stage, N-stage and ARF expression status into a Cox regression model, only ARF expression remained outperforming all other clinical indicators (Hazard ratio 10.85, 95% confidence interval 3.24--36.37, *P* \< 0.0001, [Table 4](#tbl4){ref-type="table"}). In addition, significantly more N1 tumours had lost ARF expression compared with NO tumours (81%\[31/38\] of N1 tumours *versus* 33.3%\[3/9\] of NO tumours, Fisher\'s exact test *P*= 0.008).

###### 

Variables in the Equation

                                                    **P value**           **Hazard ratio (95% confidence interval)**
  --------------------------- --------------------- --------------------- --------------------------------------------
  Step 1                      Well differentiated   0.236                 
  Moderately differentiated   0.671                 1.33 (0.36--4.97)     
  Poorly differentiated       0.178                 2.32 (0.68--7.93)     
  T1                          0.969                                       
  T2                          0.823                 1.382 (0.08--23.40)   
  T3                          0.841                 1.10 (0.44--2.72)     
  N stage                     0.548                 1.47 (0.42--5.10)     
  ARF expression lost         0.001                 13.54 (2.93--62.43)   
  Step 2                      Well differentiated   0.228                 
  Moderately differentiated   0.731                 1.21 (0.41--3.61)     
  Poorly differentiated       0.149                 2.15 (0.76--6.05)     
  N stage                     0.449                 1.55 (0.50--4.86)     
  ARF expression lost         \<0.001               12.31 (3.33--45.49)   
  Step 3                      Well differentiated   0.283                 
  Moderately differentiated   0.625                 1.30 (0.450--3.79)    
  Poorly differentiated       0.174                 2.03 (0.73--5.65)     
  ARF expression lost         \<0.001               10.53 (3.08--35.99)   
  Step 4                      ARF expression lost   \<0.001               10.85 (3.24--36.37)

Multivariate Cox regression model using a backwards stepwise method. Differentiation, T-stage, N-Stage and ARF expression were entered into the model with only ARF expression remaining (Hazard ratio 10.85, 95% confidence interval 3.24--36.37, *P*\< 0.0001).

ARF expression and gene methylation status in NE, BE and AC cell lines
----------------------------------------------------------------------

We used carcinoma cell lines and immortalized cell lines of BE origin (Gohtert, Gihtert, Chtert), as well as an immortalized NE cell line (HET1A), to further investigate mechanisms leading to reduced ARF expression in BE and AC. Non-quantitative RT-PCR analyses ([Fig. 2A](#fig02){ref-type="fig"}, ARF) revealed loss of ARF expression in 3/6 carcinoma cell lines (SEG1, TE7, OC1), and retention of ARF expression in 3/3 BE cell lines, and in the NE cell line (HET1A). All GAPDH (glyceraldehyde phosphate dehydrogenase) controls were positive. Loss of ARF expression in SEG1, OC1 and TE7 did not occur by homozygous gene deletion, as PCR analysis of genomic DNA showed that ARF exon 1β and exon 2 sequences were present ([Fig. 2A](#fig02){ref-type="fig"}, exon 1β, exon 2).

![ARF expression and gene methylation status in NE, BE and carcinoma cell lines. (**A**) RT-PCR analysis of ARF expression (ARF) and GAPDH expression (GAPDH) in the normal oesophageal epithelial cell line, HET1A, in the BE cell lines Gohtert (Go), Gihtert (Gi) and Chtert (Ch), in the AC cell lines OC3, FLO-1, OE33, SEG1, TE7 and in the oesophageal squamous cell carcinoma cell line, OC1. MSP analysis using methylated-specific (M) and unmethylated-specific (U) primers for the 5′-UTR/exon 1 μl region of the ARF gene in the same series of cell lines. Triplicate repeats produced similar results. (Lower panel) PCR analysis of genomic DNA from SEG1, TE7 and OC1 using primers for ARF exon 1ß (top row), and ARF exon 2 (lower row). (**B**) RT-PCR analysis of ARF expression (ARF) and GAPDH expression (GAPDH) of 5 subclones of the TE7 cell line. Triplicate repeats produced similar results. (**C**) (Top) Schematic representation of CpG sites along the 5′-UTR and exon 1ß region of the ARF gene. (Middle) Schematic representation of locations of methylated CpG sites (•) and unmethylated CpG sites (•) obtained by direct sequencing of the MSP products (M and U bands) from the indicated BE and carcinoma cells lines, amplified with methylated-specific primers (M) or unmethylated-specific primers (U). (Bottom) Positions along the ARF sequence of forward (**i-\>**) and reverse (**\<-.**) primers used for MSP analysis. '0' represents the start of translation. (**D**) Quantitative MSP analysis of ARF in genomic DNA from BE and carcinoma cell lines. Bars represent the average M/U ratios of triplicate assays, with standard deviations shown. (Right panel) Bisulphite-generated sequence profile of a representative region of the ARF gene from OC3 cells. Original and bisulphite-generated sequences are shown above the sequence profile. Asterisks indicate CpG sites. Doublet arrows indicate locations where both C and T appear in the bisulphite-generated sequence.](jcmm0013-0398-f2){#fig02}

To determine how CpG island methylation of the ARF gene correlates with silencing of ARF in AC and BE, we carried out a methylation-specific PCR analysis (MSP) on bisulphite-treated genomic DNA derived from these cell lines (the amplified region, which falls within the 5′-UTR (untranslated region) and exon 1R, is indicated by arrows in [Fig. 2C](#fig02){ref-type="fig"}). We found that normal oesophageal epithelial cells (HET1A) displayed only the unmethylated band, while all of the BE and carcinoma cell lines displayed both methylated and unmethylated bands ([Fig. 2A, M, U](#fig02){ref-type="fig"}). We have also observed lack of methylation of ARF in an additional cell line, BJ-1, derived from immortalized normal fibroblasts (not shown), adding additional support to the likelihood that methylation of this region in cultured BE and carcinoma cell lines correlates with the disease process. Furthermore, a well-characterized colorectal carcinoma cell line, SW48 with methylated ARF \[[@b22]\] and no ARF expression \[[@b25]\], displayed only the M band (not shown), indicating that the presence of the M and U bands is not a universal feature of all cell lines. There are, nevertheless, several other published examples of monoallelic gene methylation. In particular, monoallelic methylation of the APC gene occurs in gastric mucosa associated with neoplastic lesions \[[@b26]\], and monoallelic methylation of the p16INK4a promoter in HCT116 colon cancer cells has been reported \[[@b27]\].

We ruled out cellular heterogeneity as a source of the methylated and unmethylated bands by showing that single cell-derived clones of the TE7 cell line (ARF---) were identical to the parental TE7 cell line with respect to ARF expression ([Fig. 2B](#fig02){ref-type="fig"}, ARF), and the presence of both methylated and unmethylated ARF bands following MSP analysis ([Fig. 2B, M, U](#fig02){ref-type="fig"}). A similar subcloning analysis (not shown) carried out on 5 subclones of the OC3 (ARF+) and OC1 (ARF---) cell lines confirmed that their respective subclones also resembled the parental line from which they were derived. The pattern of methylation observed in the parental lines therefore appears unlikely to represent a heterogeneous methylation pattern of ARF alleles within a mixed population of cells.

Bisulphite treatment converts unmethylated but not methylated cytosine to uracil and therefore generates a different sequence on methylated and unmethylated DNA. To rule out heterogeneity of CpG methylation across the ARF sequence as a source of the M and U bands, we carried out a direct sequence analysis of the MSP products (M and U bands) from bisulphite-treated genomic DNA of each of the nine cell lines shown in [Figure 2A](#fig02){ref-type="fig"}, using the same methylation-specific primers as were used in [Figure 2A](#fig02){ref-type="fig"}. The results, shown schematically in [Figure 2C](#fig02){ref-type="fig"}, show that the M band corresponds to a sequence methylated at more than 90% of the available CpG sites, whereas the U band corresponds to a completely unmethylated sequence.

A quantitative MSP analysis of bisulphite-treated genomic DNA using the MSP primers from [Figure 2A](#fig02){ref-type="fig"}, demonstrated that the two gene states are present in roughly equal amounts in all nine cell lines, consistent with a diploid gene dosage for ARF in these cell lines ([Fig. 2D](#fig02){ref-type="fig"}). To further confirm the presence of both methylated and unmethylated alleles of ARF in these cells, we carried out bisulphite sequencing of a 270 base pair region from minus 67 to plus 203 (relative to start of translation) of genomic DNA from OC3 cells using universal primers chosen so as to be complementary to 5′ and 3′ flanking regions without CpG sites. These primers were therefore insensitive to the methylation state of the amplified region and simultaneously amplified both methylated and unmethylated sequences with equal efficiency in one reaction. [Figure 2D](#fig02){ref-type="fig"} (right-hand panel) shows the results for a portion of the amplified region from +56 to +97, which includes 4 CpG sites and 6 isolated Cs. Bisulphite treatment converted all 6 isolated Cs to U (T), indicating a high efficiency of conversion. In contrast, for each C present in a methylatable CpG sequence, bisulphite treatment gave rise to both a C and a U (T), as would be expected if only one of the two alleles were protected by methylation. Similar results were observed for the remainder of the sequence, and for Gihtert and SEG1 (not shown). Taken together, the results of the cell cloning analysis ([Fig. 2B](#fig02){ref-type="fig"}), the direct sequence analysis of MSP products ([Fig. 2C](#fig02){ref-type="fig"}), and the gene dosage analysis and bisulphite sequence analysis of genomic DNA ([Fig. 2D](#fig02){ref-type="fig"}), are highly suggestive of a stable pattern of CpG methylation of a single ARF allele in individual cells of BE or carcinoma origin.

Activation of ARF expression by 5-aza-2′-deoxycytidine
------------------------------------------------------

To demonstrate a functional role for the observed CpG methylation of ARF, we carried out an experiment with the DNA demethylating agent, 5-aza-2′-deoxycytidine (5-aza-CdR), followed by RT-PCR in the 3 BE cell lines and the 6 carcinoma cell lines ([Fig. 3A](#fig03){ref-type="fig"}). Treatment of cell lines with 1μM 5-aza-CdR for 24 hrs, followed by culturing for an additional 48 hrs, resulted in activation of ARF expression in the 3 carcinoma cell lines that had lacked ARF expression (SEG1, TE7, OC1, compare [Figure 3A](#fig03){ref-type="fig"} (ARF) and [Figure 3A](#fig03){ref-type="fig"} (ARF+aza)). GAPDH expression served as a control ([Fig. 3A](#fig03){ref-type="fig"}\[GAPDH+aza\]). This treatment also resulted in undetectable levels of CpG methylation of ARF in all 9 BE and carcinoma cell lines ([Fig. 3A, M, U](#fig03){ref-type="fig"}), evaluated by MSP. Furthermore, when Q-PCR was used to quantitate 5-aza-CdR-induced changes in ARF expression (relative to the GAPDH internal control) in the 3 BE cell lines (Go, Gi, Ch) and the 3 carcinoma cell lines that originally expressed ARF (OC3, FLO-1, OC33), we observed an approximate doubling of ARF expression levels ([Fig. 3B](#fig03){ref-type="fig"}), as expected if CpG methylation were to silence only one of the ARF alleles. Taken together, these results suggest that methylation silences the ARF allele on which it occurs, but do not explain how the unmethylated alleles are silenced in SEG1, TE7 and OC1 cells.

![Epigenetic changes affecting the ARF gene and associated histones in BE and carcinoma cell lines, and responses to 5-aza-CdR treatment. (**A**) RT-PCR analysis of ARF expression (ARF+aza) and GAPDH expression (GAPDH+aza) in the indicated BE and carcinoma cell lines after treatment with 5-aza-CdR. MSP analysis using methylated-specific (M+aza) and unmethylated-specific (U+aza) primers for the 5′-UTR/exon 1 **(J** region of the ARF gene in the same series of cell lines after treatment with 5-aza-CdR. (**B**) Quantitation by Q-PCR of 5-aza-CdR-induced changes in ARF expression (relative to GAPDH internal control) in the 3 BE cell lines and the 3 carcinoma cell lines that originally expressed ARF (bars represent averages of triplicate assays, with standard deviations shown). (**C**) ChIP analysis of ARF 5′-UTR/exon 1ß DNA sequences associated with histone H3 lysine 9 trimethylation (ARF H3-K9-Me3) and histone H3 lysine 9 dimethylation + lysine 27 methylation (ARF H3-K9-Me2/H3-K9--27-Me) in BE and carcinoma cell lines prior to treatment with 5-aza-CdR. Input DNA (ARF input) serves as a control. Lower panels show MSP analysis of ARF DNA sequences associated with histone H3 lysine 9 trimethylation (M,U) and histone H3 lysine 9 dimethylation + lysine 27 methylation (M,U) in SEG1, TE7, and OC1 cells. (**D**) ChIP analysis carried out on BE and carcinoma cell lines as in panel C, after treatment with 5-aza-CdR. Analyses were repeated 2--3 times with independent preparations to confirm reproducibility.](jcmm0013-0398-f3){#fig03}

Correlation of histone H3 methylation with complete silencing of ARF
--------------------------------------------------------------------

Histone H3 di and trimethylation on lysine 9 (K9), and di and trimethylation on lysine 27 (K27) have been implicated as important epigenetic mechanisms of gene silencing in cancer \[[@b28]\].

We therefore carried out a Chromatin Immunoprecipitation (ChIP) analysis using an antibody specific for histone H3 trimethylated lysine 9 (H3-K9-Me3), or using an antibody with dual specificity for the dimethylated form of histone H3 lysine K9 (H3-K9-Me2) and the di and trimethylated forms of lysine 27 (H3-K27-Me), followed by PCR analysis of the associated ARF sequences, to investigate the presence of this modification on ARF alleles in the series of cell lines examined above. As shown in [Figure 3C](#fig03){ref-type="fig"}, the ARF gene was found to be associated with chromatin containing histone H3-K9-Me3, H3-K9-Me2 and H3-K27Me only in the three carcinoma cell lines, SEG1, TE7 and OC1 ([Fig. 3C](#fig03){ref-type="fig"}), in which complete ARF gene silencing occurred. In all other cell lines, namely the three BE cell lines (Go, Gi, Ch), and three of the carcinoma cell lines (OC3, FLO-1, OC33) where partial silencing of ARF through CpG methylation was observed, there was no evidence for histone methylation ([Fig. 3C](#fig03){ref-type="fig"}). Input ARF levels were the same in all cases ([Fig. 3C](#fig03){ref-type="fig"}, ARF input). Controls (no antibody) were negative in all cases (not shown). The results suggest that histone methylation-induced silencing of ARF could also predispose to malignant transformation and to disease progression in AC.

Association of methylated histone H3 with unmethylated ARF DNA
--------------------------------------------------------------

To determine whether histone methylation occurs on both DNA methylated and DNA unmethylated alleles of ARF, we carried out a further MSP analysis of the DNA isolated from the histone-antibody immunoprecipitated material and treated with bisulphite. We found that the ARF allele associated with histone H3-K9-Me3, histone H3-K9-Me2 or with histone H3-K27-Me in SEG1, TE7, and OC1 cells is unmethylated at CpG sites ([Fig. 3C, M, U](#fig03){ref-type="fig"}). Nevertheless, treatment of SEG1, TE7, and OC1 cells with the DNA demethylating agent, 5-aza-CdR, resulted in a complete reversal of these methylated histone modifications, as revealed by ChIP analysis, even though that allele lacked CpG island methylation ([Fig. 3D](#fig03){ref-type="fig"}), consistent with a previous report \[[@b29]\]. Input ARF levels were the same in all cases ([Fig. 3D](#fig03){ref-type="fig"}, ARF input+aza), and controls (no-antibody) were negative (not shown). The results indicate that CpG methylation and histone H3 methylation occur in a mutually exclusive manner on the ARF gene in adenocarcinoma cell lines, and that each can be independently reversed by 5-aza-CdR.

Discussion
==========

This study demonstrates that the transition from normal oesophageal epithelium to BE to AC correlates with a progressive decrease in ARF expression. Complete silencing of ARF was found in 75% in the AC specimens, and correlated with poor prognosis. In our dataset, univariate analysis revealed that ARF expression was prognostically significant and in fact outperformed all other clinical variables in a multivariate analysis. The results support an important role for ARF in suppressing oesophageal cancer, and suggest that loss of ARF expression could provide a useful prognostic indicator.

Loss of p16INK4a expression (deletion, silencing, mutation) has been found in over 70% of BE patients \[[@b31]\], and because it shares its exon 2 region with ARF (reviewed in \[[@b32]\]), deletions or mutations in this region could, in principle, affect both genes, and obscure the respective roles of each gene in cancer. However, there are several reasons why abnormalities in the two genes may not correlate. First, the exon 2 region is read in an alternate reading frame for p16INK4a and ARF, so mutations in this region do not necessarily affect both proteins. Second, the first exon of ARF, which retains tumour suppressor activity \[[@b33]\], is expressed from a unique promoter, and it located some 20 kilobases upstream of the first exon of the p16INK4A gene, so deletion or methylation of one of the genes can occur without affecting the other, and this has been documented \[[@b34]\]. Our preliminary studies on a small sample set of BE specimens suggests that ARF and p16INK4a abnormalities arise independently of each other in pre-malignant lesions, but a further full scale study is needed to confirm this.

Loss of wild-type p53 expression occurs in some 50--70% patients with BE and AC, and correlates with increased aneuploidy \[[@b37]\], increased risk of progression \[[@b37]\], and with poor prognosis \[[@b38]\]. In our analysis of BE specimens, complete loss of ARF expression occurred in some 20% of BE specimens and 75% of AC specimens, indicating that its occurrence was frequent and likely to occur in many specimens simultaneously with mutation or deletion of p53. ARF plays a well-described role in the p53 pathway and in certain cancers \[[@b39]\], a reciprocal pattern of abnormalities has been observed for p53 and ARF, consistent with their action in a common pathway. However, the high frequency of both abnormalities in oesophageal cancer suggests that the two abnormalities contribute independently to disease progression in this disease, and is consistent with published evidence of a p53-independent activity for ARF in mammalian cells \[[@b41]\].

CpG methylation is a common mechanism of tumour suppressor gene silencing in cancer \[[@b15]\], and CpG methylation of the first exon and proximal promoter of ARF is well documented in other cancers and cancer-derived cell lines \[[@b43]\]. Methylation of lysines 9 and 27 of the N-terminal domain of histone H3, is also a mark of silenced genes and aberrant methylation of these residues has been implicated in gene silencing in cancer \[[@b28]\]. CpG methylation can be associated with histone H3 methylation of K9 and K27, and epigenetic changes at the level of DNA and histone can cooperate in gene silencing \[[@b45]\]. However, long-range epigenetic silencing of gene expression due solely to histone methylation without DNA methylation has also been described \[[@b46]\]. Our results suggest that either DNA or histone H3 methylation can provide the primary mechanism of ARF gene silencing in oesophageal cancer, and that each appears to be sufficient to maintain stable silencing. The TE7 cell line we have used has recently been reported to be of squamous cell carcinoma origin \[[@b47]\], but was still considered to be a useful addition to our panel of lines to determine the mechanism of silencing, however.

Consistent with an earlier study \[[@b29]\], we find that both DNA and histone methylations are reversible with 5-aza-CdR, and that this treatment reactivates ARF expression. These results provide additional rationale for the clinical application of demethylating agents such as 5-aza-cytidine or 5-aza-2′-deoxycytidine \[[@b48]\], or for specific histone demethylating approaches \[[@b28]\] to prevent tumourigenic transformation of pre-malignant lesions and possibly to reverse oesophageal malignancy.
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